CNTB

Connect Biopharma Holdings Limited (CNTB) | Rumor.io

Connect Biopharma Holdings

CNTB

Attention (50-day avg)0.01%

Attention rank (50-day avg)#419

Bullish sentiment (50-day avg)64%

Price to earnings ratio-1.08

Market capitalization68M

Earnings per share-1.19

Dividend yield (TTM)—

Revenue (annual)64K

Net income (annual)-55.5M

Social

What share of all stock conversation is about CNTB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0.02% +0.02	0% +0

Sep 16

Connect Biopharma Holdings Limited's (CNTB) Rademikibart treatment has been compared unfavorably to Dupixent, with some analysts arguing that Rademikibart's efficacy is not sufficient to justify its use in treating acute asthma.
The company's announcement that the primary and secondary endpoints for the COPD study are well within reach of achievability has been seen as a positive development, with some investors anticipating a potential move in the stock price.
The treatment failure rate for acute asthma has been reported to be around 10-20%, leading some analysts to question whether Rademikibart is even needed, and whether the launch will be successful if approved by the FDA.

Generated by AI

Sentiment

Of the messages about CNTB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +66.67	86.67% +9.74	64.29% -7.14	71.57% +1.68
Bearish	0% -66.67	13.33% -9.74	35.71% +7.14	28.43% -1.68

Bullish· Sep 3

The SEABREEZE trial, a biologic to enter the ER, has shown promising results, with the company already recruiting the protocol arm 300mg IV in the ER off SEABREEZE.
The company's eczema data is expected to be released, which could lead to a significant increase in value, with a potential $35M-$40M injection from Simcere (partner) when Rademikibart is approved in China.
The company is approaching a very important catalyst: Phase 2 Seabreeze STAT topline data for rademikibart in asthma and COPD, which could lead to a significant increase in value if the readouts are solid.

Bearish· Sep 3

The stock may drop an asthma fail PR, which could lead to a significant price decline, especially if it's announced on a Friday or after-hours.
Historically, the company has preannounced a CC ahead of positive data, and the lack of such an announcement suggests that the data may not be as expected.
The recent price action and volume are disconcerting, and a failure in the trial could lead to an 80% crash in the stock price.

Generated by AI

Topics

Of the messages about CNTB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	66.99%	56.08%
Technical Analysis	—	—	4.85%	34.44%
Earnings	—	—	8.74%	1.42%
Analysts	—	—	18.45%	7.74%
Controversies	—	—	0.97%	0.16%
Macro	—	—	0%	0.16%

Mar 30

Connect Biopharma Holdings Limited (CNTB) has announced a $20.2 million private placement financing, selling 6.13 million shares at $3.25 each.
The company has also reported positive topline data from its Phase 1 study of intravenous rademikibart in patients with asthma or COPD, demonstrating rapid FEV1 gains within 15 minutes.
The financing is expected to fund Connect Biopharma's product development and operations into late 2027, with the company's stock price rising following the announcement.

Generated by AI

Community

Of the messages about CNTB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	5.88%	13.56%
Newcomers	100%	100%	94.12%	86.44%

Regulars· Sep 15

The phase 2 study of Rademikibart showed significant Day 7 post-bronchodilator FEV1 improvement versus placebo and a non-significant 66% drop in 28-day treatment failure with placebo-like safety.
The regulars are concerned about the trial's design and patient population, with some suggesting it was flawed and that the FDA may ask to redo the entire phase 2 trial.
The market reaction to the positive preliminary topline data from the phase 2 study was an overreaction, with some participants expecting the company to take advantage of the low price to accumulate more shares.

Newcomers· Sep 15

The Phase 2 study of Rademikibart as an add-on treatment for acute exacerbations in adult and adolescent participants with asthma and type 2 inflammation showed a 66% relative reduction in treatment failures, although the primary endpoint was missed due to a lower-than-expected placebo treatment-failure rate.
The study demonstrated a statistically significant increase from baseline in post-bronchodilator FEV1 on Day 7 of 250 mL, and the primary endpoint that hit is the proposed Phase 3 primary endpoint.
The upcoming Phase 3 results in Asthma in Q1 2027 and potential approval in China in Q1 or latest April 2027 are considered catalysts, with the company's CEO highlighting the unmet need in acute asthma and the opportunity to combine acute efficacy with successful chronic maintenance development.

Generated by AI

Connect Biopharma Holdings Limited (NASDAQ:CNTB) reported mixed preliminary results on September 15 from its Phase 2 Seabreeze STAT asthma study. Rademikibart produced a numerical 66% reduction in treatment failure over 28 days versus placebo, but the primary endpoint missed statistical significance, with p=0.153. Connect Biopharma Holdings Limited (NASDAQ:CNTB) also reported a lung-function benefit on a […]

7d agoYahoo Finance

Oppenheimer Adjusts Price Target on Connect Biopharma to $5 From $8, Keeps Outperform Rating

Connect Biopharma Holdings (CNTB) has an average rating of buy and mean price target of $6.52, accor

7d agoYahoo Finance

H.C. Wainwright reiterates Buy on Connect Biopharma stock at $7

12d agoInvesting.com

Canaccord cuts Connect Biopharma stock price target on trial miss

13d agoInvesting.com

Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations - Slideshow (NASDAQ:CNTB) 2026-09-16

14d agoSeeking Alpha

Why Is Connect Biopharma Stock Trading Lower on Tuesday?

14d agobenzinga.com

Also Discussed

Investors talking about CNTB also mention

#	Name	Attention
1	Alumis Inc.ALMS	0%0
2	IN8bio, Inc.INAB	0%0
3	PepGen Inc.PEPG	0%new
4	Zura Bio LimitedZURA	0%new
5	Passage Bio Inc.PASG	0%0
6	ACHL - Achilles Therapeutics plc	——
7	Compass Therapeutics, Inc.CMPX	0%new
8	EQRX - EQRx, Inc.	——
9	INZY - Inozyme Pharma, Inc.	——
10	Acumen Pharmaceuticals, Inc.ABOS	0%new

Connect Biopharma Holdings Limited

Healthcare
Biotechnology

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases. The company concentrates on immune-mediated conditions, with its lead programs centered on antibodies designed to target pathways involved in asthma and chronic obstructive pulmonary disease. Its current pipeline is built around rademikibart, a monoclonal antibody aimed at interleukin-4 receptor alpha, as well as other research efforts in T cell-driven inflammatory disorders. Connect Biopharma works across respiratory and broader inflammation-related markets, reflecting a focus on diseases where immune signaling plays a central role. Headquartered in San Diego, California, Connect Biopharma Holdings Limited is positioned as a specialist developer of novel biologic treatments within the biotechnology sector.

Website

Location

3580 Carmel Mountain Road

San Diego, CA, 92130

United States

Social

What share of all stock conversation is about CNTB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0.02% +0.02	0% +0

Sep 16

Connect Biopharma Holdings Limited's (CNTB) Rademikibart treatment has been compared unfavorably to Dupixent, with some analysts arguing that Rademikibart's efficacy is not sufficient to justify its use in treating acute asthma.
The company's announcement that the primary and secondary endpoints for the COPD study are well within reach of achievability has been seen as a positive development, with some investors anticipating a potential move in the stock price.
The treatment failure rate for acute asthma has been reported to be around 10-20%, leading some analysts to question whether Rademikibart is even needed, and whether the launch will be successful if approved by the FDA.

Generated by AI

Sentiment

Of the messages about CNTB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +66.67	86.67% +9.74	64.29% -7.14	71.57% +1.68
Bearish	0% -66.67	13.33% -9.74	35.71% +7.14	28.43% -1.68

Bullish· Sep 3

The SEABREEZE trial, a biologic to enter the ER, has shown promising results, with the company already recruiting the protocol arm 300mg IV in the ER off SEABREEZE.
The company's eczema data is expected to be released, which could lead to a significant increase in value, with a potential $35M-$40M injection from Simcere (partner) when Rademikibart is approved in China.
The company is approaching a very important catalyst: Phase 2 Seabreeze STAT topline data for rademikibart in asthma and COPD, which could lead to a significant increase in value if the readouts are solid.

Bearish· Sep 3

The stock may drop an asthma fail PR, which could lead to a significant price decline, especially if it's announced on a Friday or after-hours.
Historically, the company has preannounced a CC ahead of positive data, and the lack of such an announcement suggests that the data may not be as expected.
The recent price action and volume are disconcerting, and a failure in the trial could lead to an 80% crash in the stock price.

Generated by AI

Topics

Of the messages about CNTB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	66.99%	56.08%
Technical Analysis	—	—	4.85%	34.44%
Earnings	—	—	8.74%	1.42%
Analysts	—	—	18.45%	7.74%
Controversies	—	—	0.97%	0.16%
Macro	—	—	0%	0.16%

Mar 30

Connect Biopharma Holdings Limited (CNTB) has announced a $20.2 million private placement financing, selling 6.13 million shares at $3.25 each.
The company has also reported positive topline data from its Phase 1 study of intravenous rademikibart in patients with asthma or COPD, demonstrating rapid FEV1 gains within 15 minutes.
The financing is expected to fund Connect Biopharma's product development and operations into late 2027, with the company's stock price rising following the announcement.

Generated by AI

Community

Of the messages about CNTB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	5.88%	13.56%
Newcomers	100%	100%	94.12%	86.44%

Regulars· Sep 15

The phase 2 study of Rademikibart showed significant Day 7 post-bronchodilator FEV1 improvement versus placebo and a non-significant 66% drop in 28-day treatment failure with placebo-like safety.
The regulars are concerned about the trial's design and patient population, with some suggesting it was flawed and that the FDA may ask to redo the entire phase 2 trial.
The market reaction to the positive preliminary topline data from the phase 2 study was an overreaction, with some participants expecting the company to take advantage of the low price to accumulate more shares.

Newcomers· Sep 15

The Phase 2 study of Rademikibart as an add-on treatment for acute exacerbations in adult and adolescent participants with asthma and type 2 inflammation showed a 66% relative reduction in treatment failures, although the primary endpoint was missed due to a lower-than-expected placebo treatment-failure rate.
The study demonstrated a statistically significant increase from baseline in post-bronchodilator FEV1 on Day 7 of 250 mL, and the primary endpoint that hit is the proposed Phase 3 primary endpoint.
The upcoming Phase 3 results in Asthma in Q1 2027 and potential approval in China in Q1 or latest April 2027 are considered catalysts, with the company's CEO highlighting the unmet need in acute asthma and the opportunity to combine acute efficacy with successful chronic maintenance development.

Generated by AI

Connect Biopharma Holdings

Social

Sep 16

Sentiment

Bullish· Sep 3

Bearish· Sep 3

Topics

Mar 30

Community

Regulars· Sep 15

Newcomers· Sep 15

News

Connect Biopharma (CNTB) Misses Key Asthma Trial Goal. Can its Drug Still Move Forward?

Oppenheimer Adjusts Price Target on Connect Biopharma to $5 From $8, Keeps Outperform Rating

H.C. Wainwright reiterates Buy on Connect Biopharma stock at $7

Canaccord cuts Connect Biopharma stock price target on trial miss

Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations - Slideshow (NASDAQ:CNTB) 2026-09-16

Why Is Connect Biopharma Stock Trading Lower on Tuesday?

Also Discussed

Connect Biopharma Holdings Limited

Company Information

Location

News

Connect Biopharma (CNTB) Misses Key Asthma Trial Goal. Can its Drug Still Move Forward?

Oppenheimer Adjusts Price Target on Connect Biopharma to $5 From $8, Keeps Outperform Rating

H.C. Wainwright reiterates Buy on Connect Biopharma stock at $7

Canaccord cuts Connect Biopharma stock price target on trial miss

Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations - Slideshow (NASDAQ:CNTB) 2026-09-16

Why Is Connect Biopharma Stock Trading Lower on Tuesday?

Also Discussed

Social

Sep 16

Sentiment

Bullish· Sep 3

Bearish· Sep 3

Topics

Mar 30

Community

Regulars· Sep 15

Newcomers· Sep 15